RaySearch Laboratories AB (publ)
RaySearch Laboratories AB (publ) (RSLBF) Stock Competitors & Peer Comparison
See (RSLBF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RSLBF | $36.85 | +14.98% | 1.2B | 52.65 | $0.68 | +0.88% |
| PMCUF | $202.84 | -1.51% | 21.2B | 332.52 | $0.61 | +0.15% |
| MTHRF | $13.02 | +0.00% | 8.8B | 32.55 | $0.40 | +1.08% |
| MTHRY | $6.19 | +0.49% | 8.5B | 31.35 | $0.20 | N/A |
| PANHF | $0.98 | +0.00% | 2.1B | 98.10 | $0.01 | +127.07% |
| PIAHY | $2.60 | +0.00% | 1.4B | 130.00 | $0.02 | +191.20% |
| CMPVF | $23.75 | -0.44% | 1.2B | 40.95 | $0.58 | +4.93% |
| CMPUY | $23.00 | -7.26% | 1.2B | 38.98 | $0.59 | N/A |
| CRWRF | $32.40 | -1.14% | 1.1B | 75.35 | $0.43 | +1.17% |
| SUSRF | $15.47 | +0.00% | 789.4M | 53.34 | $0.29 | N/A |
Stock Comparison
RSLBF vs PMCUF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PMCUF has a market cap of 21.2B. Regarding current trading prices, RSLBF is priced at $36.85, while PMCUF trades at $202.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PMCUF's P/E ratio is 332.52. In terms of profitability, RSLBF's ROE is +0.26%, compared to PMCUF's ROE of +0.48%. Regarding short-term risk, RSLBF and PMCUF have similar daily volatility (0.00).Check PMCUF's competition here
RSLBF vs MTHRF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MTHRF has a market cap of 8.8B. Regarding current trading prices, RSLBF is priced at $36.85, while MTHRF trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MTHRF's P/E ratio is 32.55. In terms of profitability, RSLBF's ROE is +0.26%, compared to MTHRF's ROE of +0.11%. Regarding short-term risk, RSLBF and MTHRF have similar daily volatility (0.00).Check MTHRF's competition here
RSLBF vs MTHRY Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MTHRY has a market cap of 8.5B. Regarding current trading prices, RSLBF is priced at $36.85, while MTHRY trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MTHRY's P/E ratio is 31.35. In terms of profitability, RSLBF's ROE is +0.26%, compared to MTHRY's ROE of +0.11%. Regarding short-term risk, RSLBF is less volatile compared to MTHRY. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MTHRY's competition here
RSLBF vs PANHF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PANHF has a market cap of 2.1B. Regarding current trading prices, RSLBF is priced at $36.85, while PANHF trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PANHF's P/E ratio is 98.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to PANHF's ROE of -0.00%. Regarding short-term risk, RSLBF is less volatile compared to PANHF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check PANHF's competition here
RSLBF vs PIAHY Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PIAHY has a market cap of 1.4B. Regarding current trading prices, RSLBF is priced at $36.85, while PIAHY trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PIAHY's P/E ratio is 130.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to PIAHY's ROE of -0.00%. Regarding short-term risk, RSLBF and PIAHY have similar daily volatility (0.00).Check PIAHY's competition here
RSLBF vs CMPVF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CMPVF has a market cap of 1.2B. Regarding current trading prices, RSLBF is priced at $36.85, while CMPVF trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CMPVF's P/E ratio is 40.95. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPVF's ROE of +0.04%. Regarding short-term risk, RSLBF and CMPVF have similar daily volatility (0.00).Check CMPVF's competition here
RSLBF vs CMPUY Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CMPUY has a market cap of 1.2B. Regarding current trading prices, RSLBF is priced at $36.85, while CMPUY trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CMPUY's P/E ratio is 38.98. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPUY's ROE of +0.04%. Regarding short-term risk, RSLBF and CMPUY have similar daily volatility (0.00).Check CMPUY's competition here
RSLBF vs CRWRF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CRWRF has a market cap of 1.1B. Regarding current trading prices, RSLBF is priced at $36.85, while CRWRF trades at $32.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CRWRF's P/E ratio is 75.35. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRWRF's ROE of +0.04%. Regarding short-term risk, RSLBF and CRWRF have similar daily volatility (0.00).Check CRWRF's competition here
RSLBF vs SUSRF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SUSRF has a market cap of 789.4M. Regarding current trading prices, RSLBF is priced at $36.85, while SUSRF trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SUSRF's P/E ratio is 53.34. In terms of profitability, RSLBF's ROE is +0.26%, compared to SUSRF's ROE of +0.03%. Regarding short-term risk, RSLBF is less volatile compared to SUSRF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check SUSRF's competition here
RSLBF vs SMSZF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SMSZF has a market cap of 705.3M. Regarding current trading prices, RSLBF is priced at $36.85, while SMSZF trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SMSZF's P/E ratio is 17.83. In terms of profitability, RSLBF's ROE is +0.26%, compared to SMSZF's ROE of +0.13%. Regarding short-term risk, RSLBF is less volatile compared to SMSZF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check SMSZF's competition here
RSLBF vs VHIBF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, VHIBF has a market cap of 544.3M. Regarding current trading prices, RSLBF is priced at $36.85, while VHIBF trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas VHIBF's P/E ratio is 331.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to VHIBF's ROE of +0.02%. Regarding short-term risk, RSLBF is less volatile compared to VHIBF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check VHIBF's competition here
RSLBF vs KSIOF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, KSIOF has a market cap of 395.2M. Regarding current trading prices, RSLBF is priced at $36.85, while KSIOF trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas KSIOF's P/E ratio is -208.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to KSIOF's ROE of -0.05%. Regarding short-term risk, RSLBF is less volatile compared to KSIOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check KSIOF's competition here
RSLBF vs SMDCF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SMDCF has a market cap of 280.9M. Regarding current trading prices, RSLBF is priced at $36.85, while SMDCF trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, RSLBF's ROE is +0.26%, compared to SMDCF's ROE of N/A. Regarding short-term risk, RSLBF and SMDCF have similar daily volatility (0.00).Check SMDCF's competition here
RSLBF vs DLHTF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, DLHTF has a market cap of 254.8M. Regarding current trading prices, RSLBF is priced at $36.85, while DLHTF trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, RSLBF's ROE is +0.26%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, RSLBF and DLHTF have similar daily volatility (0.00).Check DLHTF's competition here
RSLBF vs COGZF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, COGZF has a market cap of 188.5M. Regarding current trading prices, RSLBF is priced at $36.85, while COGZF trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas COGZF's P/E ratio is 27.75. In terms of profitability, RSLBF's ROE is +0.26%, compared to COGZF's ROE of +0.17%. Regarding short-term risk, RSLBF and COGZF have similar daily volatility (0.00).Check COGZF's competition here
RSLBF vs VPAHF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, VPAHF has a market cap of 188.2M. Regarding current trading prices, RSLBF is priced at $36.85, while VPAHF trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, RSLBF and VPAHF have similar daily volatility (0.00).Check VPAHF's competition here
RSLBF vs BNVIF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, BNVIF has a market cap of 169M. Regarding current trading prices, RSLBF is priced at $36.85, while BNVIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas BNVIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, RSLBF is less volatile compared to BNVIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check BNVIF's competition here
RSLBF vs ACMLF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ACMLF has a market cap of 150.9M. Regarding current trading prices, RSLBF is priced at $36.85, while ACMLF trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ACMLF's P/E ratio is 35.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACMLF's ROE of +0.21%. Regarding short-term risk, RSLBF is less volatile compared to ACMLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check ACMLF's competition here
RSLBF vs ONVVF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ONVVF has a market cap of 121.3M. Regarding current trading prices, RSLBF is priced at $36.85, while ONVVF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to ONVVF's ROE of -0.97%. Regarding short-term risk, RSLBF is less volatile compared to ONVVF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check ONVVF's competition here
RSLBF vs CSAMF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CSAMF has a market cap of 98.8M. Regarding current trading prices, RSLBF is priced at $36.85, while CSAMF trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, RSLBF's ROE is +0.26%, compared to CSAMF's ROE of -1.57%. Regarding short-term risk, RSLBF and CSAMF have similar daily volatility (0.00).Check CSAMF's competition here
RSLBF vs MDPEF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MDPEF has a market cap of 61.3M. Regarding current trading prices, RSLBF is priced at $36.85, while MDPEF trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MDPEF's P/E ratio is 6.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDPEF's ROE of N/A. Regarding short-term risk, RSLBF is less volatile compared to MDPEF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MDPEF's competition here
RSLBF vs HITC Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HITC has a market cap of 52.8M. Regarding current trading prices, RSLBF is priced at $36.85, while HITC trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HITC's P/E ratio is -14.75. In terms of profitability, RSLBF's ROE is +0.26%, compared to HITC's ROE of -0.84%. Regarding short-term risk, RSLBF is less volatile compared to HITC. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check HITC's competition here
RSLBF vs RQHTF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, RQHTF has a market cap of 30M. Regarding current trading prices, RSLBF is priced at $36.85, while RQHTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas RQHTF's P/E ratio is -0.07. In terms of profitability, RSLBF's ROE is +0.26%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, RSLBF is less volatile compared to RQHTF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check RQHTF's competition here
RSLBF vs TREIF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, TREIF has a market cap of 27.2M. Regarding current trading prices, RSLBF is priced at $36.85, while TREIF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas TREIF's P/E ratio is -2.58. In terms of profitability, RSLBF's ROE is +0.26%, compared to TREIF's ROE of -9.28%. Regarding short-term risk, RSLBF is less volatile compared to TREIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check TREIF's competition here
RSLBF vs CMHSF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CMHSF has a market cap of 26.6M. Regarding current trading prices, RSLBF is priced at $36.85, while CMHSF trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CMHSF's P/E ratio is 3.11. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMHSF's ROE of +0.10%. Regarding short-term risk, RSLBF is less volatile compared to CMHSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CMHSF's competition here
RSLBF vs RTNXF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, RTNXF has a market cap of 22.5M. Regarding current trading prices, RSLBF is priced at $36.85, while RTNXF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, RSLBF's ROE is +0.26%, compared to RTNXF's ROE of +1.94%. Regarding short-term risk, RSLBF is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check RTNXF's competition here
RSLBF vs VASO Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, VASO has a market cap of 21.5M. Regarding current trading prices, RSLBF is priced at $36.85, while VASO trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas VASO's P/E ratio is 12.25. In terms of profitability, RSLBF's ROE is +0.26%, compared to VASO's ROE of +0.04%. Regarding short-term risk, RSLBF is less volatile compared to VASO. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check VASO's competition here
RSLBF vs HDSLF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HDSLF has a market cap of 21.1M. Regarding current trading prices, RSLBF is priced at $36.85, while HDSLF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, RSLBF's ROE is +0.26%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, RSLBF is less volatile compared to HDSLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check HDSLF's competition here
RSLBF vs DGNOF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, DGNOF has a market cap of 18.6M. Regarding current trading prices, RSLBF is priced at $36.85, while DGNOF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas DGNOF's P/E ratio is -4.56. In terms of profitability, RSLBF's ROE is +0.26%, compared to DGNOF's ROE of +4.77%. Regarding short-term risk, RSLBF is less volatile compared to DGNOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check DGNOF's competition here
RSLBF vs THKKF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, THKKF has a market cap of 17.8M. Regarding current trading prices, RSLBF is priced at $36.85, while THKKF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas THKKF's P/E ratio is -1.51. In terms of profitability, RSLBF's ROE is +0.26%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, RSLBF and THKKF have similar daily volatility (0.00).Check THKKF's competition here
RSLBF vs MDBIF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MDBIF has a market cap of 15.1M. Regarding current trading prices, RSLBF is priced at $36.85, while MDBIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MDBIF's P/E ratio is -2.43. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDBIF's ROE of -0.14%. Regarding short-term risk, RSLBF is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MDBIF's competition here
RSLBF vs MNNDF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MNNDF has a market cap of 14.3M. Regarding current trading prices, RSLBF is priced at $36.85, while MNNDF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, RSLBF's ROE is +0.26%, compared to MNNDF's ROE of N/A. Regarding short-term risk, RSLBF is less volatile compared to MNNDF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MNNDF's competition here
RSLBF vs PBSV Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PBSV has a market cap of 13.8M. Regarding current trading prices, RSLBF is priced at $36.85, while PBSV trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PBSV's P/E ratio is -60.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, RSLBF and PBSV have similar daily volatility (0.00).Check PBSV's competition here
RSLBF vs UDOCF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, UDOCF has a market cap of 12.9M. Regarding current trading prices, RSLBF is priced at $36.85, while UDOCF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas UDOCF's P/E ratio is -2.82. In terms of profitability, RSLBF's ROE is +0.26%, compared to UDOCF's ROE of +6.57%. Regarding short-term risk, RSLBF is less volatile compared to UDOCF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check UDOCF's competition here
RSLBF vs CRVW Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CRVW has a market cap of 12.3M. Regarding current trading prices, RSLBF is priced at $36.85, while CRVW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CRVW's P/E ratio is -2.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRVW's ROE of +0.16%. Regarding short-term risk, RSLBF is less volatile compared to CRVW. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CRVW's competition here
RSLBF vs EMOR Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EMOR has a market cap of 9.8M. Regarding current trading prices, RSLBF is priced at $36.85, while EMOR trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EMOR's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EMOR's ROE of +0.28%. Regarding short-term risk, RSLBF and EMOR have similar daily volatility (0.00).Check EMOR's competition here
RSLBF vs CDXFF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CDXFF has a market cap of 9.7M. Regarding current trading prices, RSLBF is priced at $36.85, while CDXFF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CDXFF's P/E ratio is -1.35. In terms of profitability, RSLBF's ROE is +0.26%, compared to CDXFF's ROE of +0.44%. Regarding short-term risk, RSLBF and CDXFF have similar daily volatility (0.00).Check CDXFF's competition here
RSLBF vs HSCHF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HSCHF has a market cap of 9.5M. Regarding current trading prices, RSLBF is priced at $36.85, while HSCHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HSCHF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HSCHF's ROE of +0.00%. Regarding short-term risk, RSLBF and HSCHF have similar daily volatility (0.00).Check HSCHF's competition here
RSLBF vs VYND Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, VYND has a market cap of 9.2M. Regarding current trading prices, RSLBF is priced at $36.85, while VYND trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas VYND's P/E ratio is -49.99. In terms of profitability, RSLBF's ROE is +0.26%, compared to VYND's ROE of +0.48%. Regarding short-term risk, RSLBF and VYND have similar daily volatility (0.00).Check VYND's competition here
RSLBF vs HBCNF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HBCNF has a market cap of 8.4M. Regarding current trading prices, RSLBF is priced at $36.85, while HBCNF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, RSLBF's ROE is +0.26%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, RSLBF is less volatile compared to HBCNF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check HBCNF's competition here
RSLBF vs SPLTF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SPLTF has a market cap of 8M. Regarding current trading prices, RSLBF is priced at $36.85, while SPLTF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, RSLBF's ROE is +0.26%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, RSLBF is less volatile compared to SPLTF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check SPLTF's competition here
RSLBF vs CRBKF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CRBKF has a market cap of 6.8M. Regarding current trading prices, RSLBF is priced at $36.85, while CRBKF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, RSLBF's ROE is +0.26%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, RSLBF and CRBKF have similar daily volatility (0.00).Check CRBKF's competition here
RSLBF vs DOCRF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, DOCRF has a market cap of 6.2M. Regarding current trading prices, RSLBF is priced at $36.85, while DOCRF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, RSLBF's ROE is +0.26%, compared to DOCRF's ROE of -2.21%. Regarding short-term risk, RSLBF and DOCRF have similar daily volatility (0.00).Check DOCRF's competition here
RSLBF vs AIMLF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, AIMLF has a market cap of 5.2M. Regarding current trading prices, RSLBF is priced at $36.85, while AIMLF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas AIMLF's P/E ratio is -0.75. In terms of profitability, RSLBF's ROE is +0.26%, compared to AIMLF's ROE of -11.81%. Regarding short-term risk, RSLBF is less volatile compared to AIMLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check AIMLF's competition here
RSLBF vs CMPD Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CMPD has a market cap of 5M. Regarding current trading prices, RSLBF is priced at $36.85, while CMPD trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CMPD's P/E ratio is -15.96. In terms of profitability, RSLBF's ROE is +0.26%, compared to CMPD's ROE of +0.07%. Regarding short-term risk, RSLBF and CMPD have similar daily volatility (0.00).Check CMPD's competition here
RSLBF vs CNONF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CNONF has a market cap of 5M. Regarding current trading prices, RSLBF is priced at $36.85, while CNONF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CNONF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, RSLBF is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CNONF's competition here
RSLBF vs RYAHF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, RYAHF has a market cap of 5M. Regarding current trading prices, RSLBF is priced at $36.85, while RYAHF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, RSLBF's ROE is +0.26%, compared to RYAHF's ROE of +0.00%. Regarding short-term risk, RSLBF and RYAHF have similar daily volatility (0.00).Check RYAHF's competition here
RSLBF vs IQAIF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, IQAIF has a market cap of 4.9M. Regarding current trading prices, RSLBF is priced at $36.85, while IQAIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas IQAIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to IQAIF's ROE of -1.62%. Regarding short-term risk, RSLBF is less volatile compared to IQAIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check IQAIF's competition here
RSLBF vs CBDS Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CBDS has a market cap of 4.3M. Regarding current trading prices, RSLBF is priced at $36.85, while CBDS trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CBDS's P/E ratio is -1.49. In terms of profitability, RSLBF's ROE is +0.26%, compared to CBDS's ROE of +1.55%. Regarding short-term risk, RSLBF is less volatile compared to CBDS. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CBDS's competition here
RSLBF vs EBYH Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EBYH has a market cap of 2.1M. Regarding current trading prices, RSLBF is priced at $36.85, while EBYH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EBYH's P/E ratio is -6.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to EBYH's ROE of -0.03%. Regarding short-term risk, RSLBF is less volatile compared to EBYH. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check EBYH's competition here
RSLBF vs MITI Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MITI has a market cap of 1.7M. Regarding current trading prices, RSLBF is priced at $36.85, while MITI trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MITI's P/E ratio is -5.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to MITI's ROE of -0.05%. Regarding short-term risk, RSLBF is less volatile compared to MITI. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MITI's competition here
RSLBF vs EKGGF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EKGGF has a market cap of 1.4M. Regarding current trading prices, RSLBF is priced at $36.85, while EKGGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EKGGF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EKGGF's ROE of +0.81%. Regarding short-term risk, RSLBF is less volatile compared to EKGGF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check EKGGF's competition here
RSLBF vs CTVEF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CTVEF has a market cap of 1.2M. Regarding current trading prices, RSLBF is priced at $36.85, while CTVEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CTVEF's P/E ratio is -0.16. In terms of profitability, RSLBF's ROE is +0.26%, compared to CTVEF's ROE of +0.08%. Regarding short-term risk, RSLBF is less volatile compared to CTVEF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CTVEF's competition here
RSLBF vs DTRK Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, DTRK has a market cap of 1M. Regarding current trading prices, RSLBF is priced at $36.85, while DTRK trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas DTRK's P/E ratio is -4.71. In terms of profitability, RSLBF's ROE is +0.26%, compared to DTRK's ROE of -9.79%. Regarding short-term risk, RSLBF is less volatile compared to DTRK. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check DTRK's competition here
RSLBF vs LVCE Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, LVCE has a market cap of 923.9K. Regarding current trading prices, RSLBF is priced at $36.85, while LVCE trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas LVCE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to LVCE's ROE of N/A. Regarding short-term risk, RSLBF and LVCE have similar daily volatility (0.00).Check LVCE's competition here
RSLBF vs PPJE Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PPJE has a market cap of 920.5K. Regarding current trading prices, RSLBF is priced at $36.85, while PPJE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PPJE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PPJE's ROE of +0.00%. Regarding short-term risk, RSLBF and PPJE have similar daily volatility (0.00).Check PPJE's competition here
RSLBF vs MDXL Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MDXL has a market cap of 801K. Regarding current trading prices, RSLBF is priced at $36.85, while MDXL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MDXL's P/E ratio is -0.10. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDXL's ROE of +0.13%. Regarding short-term risk, RSLBF is less volatile compared to MDXL. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MDXL's competition here
RSLBF vs CSOC Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CSOC has a market cap of 774.8K. Regarding current trading prices, RSLBF is priced at $36.85, while CSOC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CSOC's P/E ratio is 0.14. In terms of profitability, RSLBF's ROE is +0.26%, compared to CSOC's ROE of -2.38%. Regarding short-term risk, RSLBF is less volatile compared to CSOC. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CSOC's competition here
RSLBF vs NEWUF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, NEWUF has a market cap of 625.3K. Regarding current trading prices, RSLBF is priced at $36.85, while NEWUF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas NEWUF's P/E ratio is -0.04. In terms of profitability, RSLBF's ROE is +0.26%, compared to NEWUF's ROE of +0.67%. Regarding short-term risk, RSLBF and NEWUF have similar daily volatility (0.00).Check NEWUF's competition here
RSLBF vs MDNWF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MDNWF has a market cap of 517.3K. Regarding current trading prices, RSLBF is priced at $36.85, while MDNWF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, RSLBF is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MDNWF's competition here
RSLBF vs MDRM Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MDRM has a market cap of 471.9K. Regarding current trading prices, RSLBF is priced at $36.85, while MDRM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MDRM's P/E ratio is -0.37. In terms of profitability, RSLBF's ROE is +0.26%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, RSLBF is less volatile compared to MDRM. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check MDRM's competition here
RSLBF vs NDATF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, NDATF has a market cap of 450.5K. Regarding current trading prices, RSLBF is priced at $36.85, while NDATF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas NDATF's P/E ratio is -1.09. In terms of profitability, RSLBF's ROE is +0.26%, compared to NDATF's ROE of -0.62%. Regarding short-term risk, RSLBF and NDATF have similar daily volatility (0.00).Check NDATF's competition here
RSLBF vs EVAHF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EVAHF has a market cap of 413.6K. Regarding current trading prices, RSLBF is priced at $36.85, while EVAHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EVAHF's P/E ratio is -1.19. In terms of profitability, RSLBF's ROE is +0.26%, compared to EVAHF's ROE of +0.28%. Regarding short-term risk, RSLBF is less volatile compared to EVAHF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check EVAHF's competition here
RSLBF vs ACHKF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ACHKF has a market cap of 377.4K. Regarding current trading prices, RSLBF is priced at $36.85, while ACHKF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ACHKF's P/E ratio is -0.05. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, RSLBF and ACHKF have similar daily volatility (0.00).Check ACHKF's competition here
RSLBF vs TSTTF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, TSTTF has a market cap of 332.9K. Regarding current trading prices, RSLBF is priced at $36.85, while TSTTF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas TSTTF's P/E ratio is -1.67. In terms of profitability, RSLBF's ROE is +0.26%, compared to TSTTF's ROE of +0.12%. Regarding short-term risk, RSLBF is less volatile compared to TSTTF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check TSTTF's competition here
RSLBF vs NHIQ Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, NHIQ has a market cap of 329.7K. Regarding current trading prices, RSLBF is priced at $36.85, while NHIQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas NHIQ's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, RSLBF is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check NHIQ's competition here
RSLBF vs LFCOF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, LFCOF has a market cap of 282K. Regarding current trading prices, RSLBF is priced at $36.85, while LFCOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, RSLBF's ROE is +0.26%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, RSLBF is less volatile compared to LFCOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check LFCOF's competition here
RSLBF vs EWLL Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EWLL has a market cap of 185.1K. Regarding current trading prices, RSLBF is priced at $36.85, while EWLL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EWLL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EWLL's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check EWLL's competition here
RSLBF vs ALDNF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ALDNF has a market cap of 160.4K. Regarding current trading prices, RSLBF is priced at $36.85, while ALDNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ALDNF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ALDNF's ROE of +0.00%. Regarding short-term risk, RSLBF and ALDNF have similar daily volatility (0.00).Check ALDNF's competition here
RSLBF vs USPS Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, USPS has a market cap of 158.5K. Regarding current trading prices, RSLBF is priced at $36.85, while USPS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas USPS's P/E ratio is -1.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to USPS's ROE of -0.63%. Regarding short-term risk, RSLBF is less volatile compared to USPS. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check USPS's competition here
RSLBF vs EMYSF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, EMYSF has a market cap of 151.7K. Regarding current trading prices, RSLBF is priced at $36.85, while EMYSF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas EMYSF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to EMYSF's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check EMYSF's competition here
RSLBF vs DSOL Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, DSOL has a market cap of 88.9K. Regarding current trading prices, RSLBF is priced at $36.85, while DSOL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas DSOL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to DSOL's ROE of +0.05%. Regarding short-term risk, RSLBF is less volatile compared to DSOL. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check DSOL's competition here
RSLBF vs PASO Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PASO has a market cap of 74.1K. Regarding current trading prices, RSLBF is priced at $36.85, while PASO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PASO's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PASO's ROE of +6.20%. Regarding short-term risk, RSLBF and PASO have similar daily volatility (0.00).Check PASO's competition here
RSLBF vs REFG Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, REFG has a market cap of 60.8K. Regarding current trading prices, RSLBF is priced at $36.85, while REFG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas REFG's P/E ratio is -0.01. In terms of profitability, RSLBF's ROE is +0.26%, compared to REFG's ROE of +0.01%. Regarding short-term risk, RSLBF and REFG have similar daily volatility (0.00).Check REFG's competition here
RSLBF vs HDVY Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HDVY has a market cap of 41.2K. Regarding current trading prices, RSLBF is priced at $36.85, while HDVY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HDVY's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HDVY's ROE of +0.00%. Regarding short-term risk, RSLBF and HDVY have similar daily volatility (0.00).Check HDVY's competition here
RSLBF vs IGRW Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, IGRW has a market cap of 39.8K. Regarding current trading prices, RSLBF is priced at $36.85, while IGRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas IGRW's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to IGRW's ROE of +7.88%. Regarding short-term risk, RSLBF is less volatile compared to IGRW. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check IGRW's competition here
RSLBF vs RVRC Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, RVRC has a market cap of 39.2K. Regarding current trading prices, RSLBF is priced at $36.85, while RVRC trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas RVRC's P/E ratio is -0.11. In terms of profitability, RSLBF's ROE is +0.26%, compared to RVRC's ROE of -0.29%. Regarding short-term risk, RSLBF is less volatile compared to RVRC. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check RVRC's competition here
RSLBF vs WMGR Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, WMGR has a market cap of 36.3K. Regarding current trading prices, RSLBF is priced at $36.85, while WMGR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas WMGR's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to WMGR's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to WMGR. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check WMGR's competition here
RSLBF vs SSYNF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SSYNF has a market cap of 33.3K. Regarding current trading prices, RSLBF is priced at $36.85, while SSYNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to SSYNF's ROE of N/A. Regarding short-term risk, RSLBF and SSYNF have similar daily volatility (0.00).Check SSYNF's competition here
RSLBF vs SOFE Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, SOFE has a market cap of 31K. Regarding current trading prices, RSLBF is priced at $36.85, while SOFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas SOFE's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, RSLBF and SOFE have similar daily volatility (0.00).Check SOFE's competition here
RSLBF vs TTBLF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, TTBLF has a market cap of 26.7K. Regarding current trading prices, RSLBF is priced at $36.85, while TTBLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, RSLBF is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check TTBLF's competition here
RSLBF vs NHEL Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, NHEL has a market cap of 16.2K. Regarding current trading prices, RSLBF is priced at $36.85, while NHEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas NHEL's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to NHEL's ROE of +0.00%. Regarding short-term risk, RSLBF and NHEL have similar daily volatility (0.00).Check NHEL's competition here
RSLBF vs FDBH Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, FDBH has a market cap of 15K. Regarding current trading prices, RSLBF is priced at $36.85, while FDBH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas FDBH's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, RSLBF and FDBH have similar daily volatility (0.00).Check FDBH's competition here
RSLBF vs ORHB Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ORHB has a market cap of 12.8K. Regarding current trading prices, RSLBF is priced at $36.85, while ORHB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ORHB's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ORHB's ROE of +0.33%. Regarding short-term risk, RSLBF and ORHB have similar daily volatility (0.00).Check ORHB's competition here
RSLBF vs HLTT Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, HLTT has a market cap of 10.7K. Regarding current trading prices, RSLBF is priced at $36.85, while HLTT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas HLTT's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, RSLBF and HLTT have similar daily volatility (0.00).Check HLTT's competition here
RSLBF vs CGNSF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, CGNSF has a market cap of 9K. Regarding current trading prices, RSLBF is priced at $36.85, while CGNSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas CGNSF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, RSLBF is less volatile compared to CGNSF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check CGNSF's competition here
RSLBF vs MOSTQ Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, MOSTQ has a market cap of 8.5K. Regarding current trading prices, RSLBF is priced at $36.85, while MOSTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas MOSTQ's P/E ratio is -0.00. In terms of profitability, RSLBF's ROE is +0.26%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, RSLBF and MOSTQ have similar daily volatility (0.00).Check MOSTQ's competition here
RSLBF vs ACNV Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ACNV has a market cap of 8.1K. Regarding current trading prices, RSLBF is priced at $36.85, while ACNV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ACNV's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ACNV's ROE of +0.00%. Regarding short-term risk, RSLBF and ACNV have similar daily volatility (0.00).Check ACNV's competition here
RSLBF vs AHGIF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, AHGIF has a market cap of 7.8K. Regarding current trading prices, RSLBF is priced at $36.85, while AHGIF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas AHGIF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, RSLBF is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check AHGIF's competition here
RSLBF vs ICCO Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ICCO has a market cap of 4K. Regarding current trading prices, RSLBF is priced at $36.85, while ICCO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ICCO's P/E ratio is -0.02. In terms of profitability, RSLBF's ROE is +0.26%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, RSLBF and ICCO have similar daily volatility (0.00).Check ICCO's competition here
RSLBF vs NMXS Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, NMXS has a market cap of 3.8K. Regarding current trading prices, RSLBF is priced at $36.85, while NMXS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas NMXS's P/E ratio is -0.01. In terms of profitability, RSLBF's ROE is +0.26%, compared to NMXS's ROE of +1.59%. Regarding short-term risk, RSLBF and NMXS have similar daily volatility (0.00).Check NMXS's competition here
RSLBF vs BBLNF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, BBLNF has a market cap of 2.6K. Regarding current trading prices, RSLBF is priced at $36.85, while BBLNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas BBLNF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, RSLBF and BBLNF have similar daily volatility (0.00).Check BBLNF's competition here
RSLBF vs PCYS Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, PCYS has a market cap of 1.1K. Regarding current trading prices, RSLBF is priced at $36.85, while PCYS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas PCYS's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to PCYS's ROE of -2.71%. Regarding short-term risk, RSLBF is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check PCYS's competition here
RSLBF vs OLMM Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, OLMM has a market cap of 1K. Regarding current trading prices, RSLBF is priced at $36.85, while OLMM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas OLMM's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to OLMM's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to OLMM. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check OLMM's competition here
RSLBF vs ETAOF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, ETAOF has a market cap of 512. Regarding current trading prices, RSLBF is priced at $36.85, while ETAOF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas ETAOF's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, RSLBF is less volatile compared to ETAOF. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check ETAOF's competition here
RSLBF vs LGBI Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, LGBI has a market cap of 50. Regarding current trading prices, RSLBF is priced at $36.85, while LGBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas LGBI's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, RSLBF is less volatile compared to LGBI. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check LGBI's competition here
RSLBF vs APYI Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, APYI has a market cap of 34. Regarding current trading prices, RSLBF is priced at $36.85, while APYI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas APYI's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to APYI's ROE of -0.60%. Regarding short-term risk, RSLBF and APYI have similar daily volatility (0.00).Check APYI's competition here
RSLBF vs VMCS Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, VMCS has a market cap of 0. Regarding current trading prices, RSLBF is priced at $36.85, while VMCS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas VMCS's P/E ratio is N/A. In terms of profitability, RSLBF's ROE is +0.26%, compared to VMCS's ROE of +3.10%. Regarding short-term risk, RSLBF is less volatile compared to VMCS. This indicates potentially lower risk in terms of short-term price fluctuations for RSLBF.Check VMCS's competition here
RSLBF vs WTEQF Comparison August 2025
RSLBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RSLBF stands at 1.2B. In comparison, WTEQF has a market cap of 0. Regarding current trading prices, RSLBF is priced at $36.85, while WTEQF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RSLBF currently has a P/E ratio of 52.65, whereas WTEQF's P/E ratio is 1.78. In terms of profitability, RSLBF's ROE is +0.26%, compared to WTEQF's ROE of N/A. Regarding short-term risk, RSLBF and WTEQF have similar daily volatility (0.00).Check WTEQF's competition here